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Angiotensin-converting enzyme 2 (ACE2) is a homolog of
ACE, which is not blocked by ACE inhibitors. High amounts of
ACE2 are present in the proximal tubule, and ACE2 catalyzes
generation of angiotensin 1–7 (Ang-(1–7)) by this segment.
Ang-(1–7) binds to a receptor distinct from the AT1 or AT2
Ang II receptor, identified as the mas receptor. We studied
the effects of Ang-(1–7) on Ang II-mediated cell signaling
pathways in proximal tubule. In primary cultures of rat
proximal tubular cells, activation of mitogen-activated
protein kinases (MAPK) was detected by immunoblotting,
in the presence or absence of agonists/antagonists.
Transforming growth factor-b1 (TGF-b1) was measured by
enzyme-linked immunosorbent assay. Ang II (5 min, 107 M)
stimulated phosphorylation of the three MAPK (p38,
extracellular signal-related kinase (ERK 1/2), and c-Jun
N-terminal kinase (JNK)). While incubation of proximal
tubular cells with Ang-(1–7) alone did not significantly affect
MAPK phosphorylation, Ang-(1–7) (107 M) completely
inhibited Ang II-stimulated phosphorylation of p38, ERK 1/2,
and JNK. This inhibitory effect was reversed by the Ang-(1–7)
receptor antagonist, D-Ala7-Ang-(1–7). Ang II significantly
increased production of TGF-b1 in proximal tubular cells,
an effect that was partly inhibited by Ang-(1–7). Ang-(1–7)
had no significant effect on cyclic 30,50-adenosine
monophosphate production in these cells. In summary,
Ang-(1–7) inhibits Ang II-stimulated MAPK phosphorylation
in proximal tubular cells. Generation of Ang-(1–7) by proximal
tubular ACE2 could thereby serve a protective role by
counteracting the effects of locally generated Ang II.
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The renin–angiotensin system plays a crucial role in the
regulation of renal and cardiovascular function. Although
angiotensin II (Ang II) is the best characterized product of
the renin–angiotensin system, Ang-(1–7), a heptapeptide that
lacks phenylalanine at position 8 of the Ang II peptide is
thought to be an important biologically active component of
this system.1 In 2000, a new pathway of Ang-(1–7) formation
was described, involving catalysis by an angiotensin-convert-
ing enzyme (ACE)-related carboxypeptidase, ACE2.2,3 ACE2
differs in its specificity and physiological role from classical
ACE, and is not blocked by ACE inhibitors. Thus, ACE2 is
responsible for the conversion of Ang-(1–10) to Ang-(1–9),
which is directly transformed to Ang-(1–7) by ACE. ACE2
also directly cleaves Ang II to form Ang-(1–7).2
ACE2 is found in the kidney, with a relative abundance
in the proximal straight tubule.4–6 Recently, we determined
that ACE2 is widely expressed in rat nephron segments, with
relatively high concentrations in the proximal tubule, and
we showed that ACE2 leads to generation of Ang-(1–7) in
this segment.6 In several tissues, the effects of Ang-(1–7)
appear to oppose those caused by Ang II. Thus, in contrast to
Ang II, Ang-(1–7) displays vasodilator, natriuretic, diuretic,
and antiproliferative actions.7–10 The vasodilatory effects of
Ang-(1–7) are associated with lowering of blood pressure,
prevention of cardiac pathophysiology, and attenuation of
the renal abnormalities associated with hypertension.11–15
Ang-(1–7) increases the release of nitric oxide16,17 and the
vasodilator prostacyclin18 and potentiates the hypotensive
effects of bradykinin.19 These findings suggest that Ang-(1–7)
may limit the pressor and proliferative effects of Ang II.
The mitogen-activated protein kinase (MAPK) cascade is
an important intracellular mediator of responses related to
cell growth and differentiation, survival, and cell death. Ang
II is a well-known activator of this signaling pathway, and
Ang II is also capable of inducing the synthesis of the
profibrotic cytokine transforming growth factor-b1 (TGF-b1)
in proximal tubule, associated with subsequent alterations in
cell growth and matrix production.20,21 Although it is now
evident that Ang-(1–7) can be produced by proximal tubular
cells, the effect of Ang-(1–7) on these Ang II-stimulated
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signaling events is unknown. Accordingly, in the current
study, we examined whether Ang-(1–7) affects Ang II-medi-
ated MAPK signaling pathways in primary cultures of rat
proximal tubular cells. Our hypothesis was that Ang-(1–7)
might inhibit these pathways, suggesting that it acts as a
counterregulatory factor to Ang II in the proximal tubule.
RESULTS
Ang II phosphorylates three distinct MAPK (p38, ERK 1/2
and JNK) in rat proximal tubular cells
Ang II induces phosphorylation of p38, extracellular signal-
related kinase (ERK) 1/2, and JNK MAPK in several cell
types.22–24 In primary cultures of rat proximal tubular cells
incubated with Ang II for 5–60 min, significant concentra-
tion-dependent phosphorylation of p38 was detected, with
peak stimulation at 5-min incubation with Ang II 107 M
(Figure 1: p38: 1.9570.22-fold stimulation, Po0.005 vs
control, n¼ 3–10). Ang II (107 M) also stimulated the phos-
phorylation of ERK 1/2 and JNK, with a peak effect at 5-min
incubation (ERK1/2: 1.7070.19-fold stimulation, Po0.001
vs control, n¼ 4; JNK: 2.7370.73-fold stimulation, Po0.05
vs control, n¼ 4). Similar stimulatory effects of Ang II were
observed on both ERK1 and 2, and on the p54 and p46 JNK
proteins. Ang II had no effect on the amount of nonphos-
phorylated MAPK proteins.
Rat proximal tubular cells express mRNA for the mas receptor
To determine if primary cultures of rat proximal tubular cells
express mRNA for the putative receptor for Ang-(1–7), mas,
reverse transcription-polymerase chain reaction (RT-PCR)
was performed on RNA isolated from these cells. In three
separate experiments, RT-PCR generated a single band
corresponding to the expected 313 bp product for the
mas cDNA in rat proximal tubular cells (results not shown).
RT-PCR also confirmed the presence of mas mRNA in freshly
isolated rat renal cortex.
Effect of Ang-(1–7) on Ang II-induced MAPK phosphorylation
Incubation of cells with Ang-(1–7) (107 M) alone caused a
small, nonsignificant increase in p38 MAPK phosphorylation
(1.1970.11-fold of control, P¼NS, n¼ 7). However, pre-
treatment with 107 M Ang-(1–7) for 20 min significantly
inhibited the Ang II-stimulated phosphorylation of p38
MAPK, and the other two MAPK (p38: 0.7370.11-fold of
control, Po0.001 vs Ang II, n¼ 7; ERK 1/2: 0.9570.12-fold
of control, Po0.05 vs Ang II, n¼ 5–6; JNK: 1.1570.13-fold
of control, Po0.01 vs Ang II, n¼ 5) (Figures 2–4). The
stimulatory effects of Ang II on MAPK phosphorylation
were also significantly inhibited in the presence of the AT1
receptor antagonist losartan (106 M) (p38: 1.0070.24-fold
of control, Po0.001 vs Ang II alone; ERK 1/2: 0.8470.16-
fold of control, Po0.05 vs Ang II alone; JNK: 0.9170.09-fold
of control, Po0.001 vs Ang II alone) (Figures 2–4). Interest-
ingly, the AT2 receptor antagonist PD123319 (10
6
M) also
caused an inhibitory effect on Ang II-stimulated p38 phos-
phorylation (Figure 2).
The selective Ang-(1–7) receptor antagonist, D-Ala7-Ang-
(1–7) (105 M), reversed the inhibitory effect of Ang-(1–7) on
Ang II-stimulated MAPK phosphorylation (Ang IIþAng-
(1–7)þ D-Ala7-Ang-(1–7): p38: 2.0770.32-fold of control,
P¼NS vs Ang II, n¼ 6; ERK 1/2: 1.3270.07-fold of control,
P¼NS vs Ang II, n¼ 5; JNK: 1.7670.16-fold of control,
P¼NS vs Ang II, n¼ 5) (Figures 5–7).
Effect of Ang-(1–7) on Ang II-stimulated synthesis of TGF-b1
Incubation of rat proximal tubular cells with Ang II (107 M)
for 48 h produced a significant increase in the levels of TGF-
b1 in the cell supernatant (Ang II: 27.373.3 pg/ml vs control:
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Figure 1 | Ang II induces concentration-dependent phosphoryla-
tion of p38 MAPK in rat proximal tubular cells. The effect of Ang II
(109–106 M) on p38 MAPK phosphorylation (pp38 MAPK) is shown,
with a representative Western blot depicted above. Cells were
treated with Ang II at the indicated concentrations for 5 min, and
Western analysis was performed for phosphorylated p38 (pp38) and
total p38 protein. Ang II had no significant effect on the amount of
total p38. Values are means7s.e. *Po0.05 compared with control
(n¼ 3–10).
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Figure 2 | Ang-(1–7) inhibits Ang II-stimulated p38 MAPK phos-
phorylation. Shown is the effect of pretreatment of rat proximal
tubular cells for 20 min with Ang-(1–7) (107 M), the AT1 receptor
antagonist losartan (LOS, 106 M), or the AT2 receptor antagonist
PD123319 (PD, 106 M), followed by administration of Ang II (107 M)
for 5 min, on phosphorylation of p38 MAPK (pp38). Representative
Western blot is shown above the graph. Values are means7s.e.
*Po0.001 vs control, **Po0.001 vs Ang II, and ***Po0.05 vs
Ang II (n¼ 7).
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3.772.3 pg/ml, Po0.001, n¼ 7). Ang-(1–7) (107 M) alone
had no effect on TGF-b1 secretion by proximal tubular cells
(Ang-(1–7): 5.972.9 pg/ml, n¼ 7). However, Ang-(1–7)
caused a partial reduction in the levels of TGF-b1 induced
by stimulation with Ang II (Ang IIþAng-(1–7): 17.37
3.5 pg/ml, Po0.05 vs control, n¼ 7) (Figure 8).
Effect of Ang-(1–7) on cAMP production in rat proximal
tubular cells
Ang-(1–7) stimulates cyclic 30,50-adenosine monophosphate
(cAMP) synthesis in freshly isolated rat inner medullary
collecting duct suspensions and in rat vascular smooth
muscle cells.25,26 To determine if Ang-(1–7) activates adenylate
cyclase in rat proximal tubular cells, cAMP was measured
after exposing cells to Ang-(1–7) for 10 or 30 min. Neither
Ang-(1–7) (107 M) nor Ang II (107 M) had any effect on
cAMP levels at either time point, whereas parathyroid
hormone (PTH) (107 M) and forskolin (104 M) stimulated
cAMP (30 min: control: 12.1471.56 pmol/mg; Ang-(1–7):
13.3371.07 pmol/mg; Ang II: 11.6371.07 pmol/mg; PTH:
24.4574.56 pmol/mg; Po0.01 vs control; forskolin: 190.587
21.78 pmol/mg; Po0.001 vs control; n¼ 3–5).
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Figure 3 | Ang-(1–7) inhibits Ang II-stimulated phosphorylation of
ERK 1/2. Shown is the effect of pretreatment of rat proximal tubular
cells for 20 min with Ang-(1–7) (107 M), the AT1 receptor antagonist
losartan (LOS, 106 M), or the AT2 receptor antagonist PD123319 (PD,
106 M), followed by administration of Ang II (107 M) for 5 min, on
phosphorylation of ERK 1/2 (pERK). Representative Western blot is
shown above the graph. Values are means7s.e. *Po0.05 vs control,
**Po0.05 vs Ang II (n¼ 5–6).
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Figure 4 | Ang-(1–7) inhibits Ang II-stimulated phosphorylation of
JNK. Shown is the effect of pretreatment of rat proximal tubular cells
for 20 min with Ang-(1–7) (107 M), the AT1 receptor antagonist
losartan (LOS, 106 M), or the AT2 receptor antagonist PD123319 (PD,
106 M), followed by administration of Ang II (107 M) for 5 min, on
phosphorylation of JNK (pJNK). Representative Western blot is shown
above the graph. Values are means7s.e. *Po0.001 vs control,
**Po0.01 vs Ang II, ***Po0.001 vs Ang II (n¼ 5).
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Figure 5 | D-Ala7-Ang-(1–7) reverses the inhibitory effect of
Ang-(1–7) on Ang II-stimulated p38 phosphorylation. Rat proximal
tubular cells were pretreated with D-Ala7-Ang-(1–7) (D-Ala7, 105 M)
for 10 min prior to administration of Ang II, with or without
Ang-(1–7) (107 M). Shown is effect on phosphorylation of p38.
*Po0.01 vs control, **Po0.05 vs Ang II or vs Ang IIþAng-(1–7)þ
D-Ala7, n¼ 6.
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Figure 6 | D-Ala7-Ang-(1–7) reverses the inhibitory effect of
Ang-(1–7) on Ang II-stimulated ERK phosphorylation. Rat proximal
tubular cells were pretreated with D-Ala7-Ang-(1–7) (D-Ala7, 105 M) for
10 min prior to administration of Ang II, with or without Ang-(1–7)
(107 M). Shown is effect on phosphorylation of ERK. *Po0.05 vs
control, **Po0.005 vs Ang II, and Po0.05 vs Ang IIþAng-(1–7)þ
D-Ala7, n¼ 5.
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DISCUSSION
The MAPK family of serine/threonine kinases consists of at
least three broad families (p38 kinase, extracellular signal-
regulated kinase (ERK 1/2), and c-Jun N-terminal kinase
(JNK)) that regulate several processes, including cellular
growth, differentiation, and survival. The MAPK family
transduces signals from the cell surface to the nucleus in
response to growth factors and cell stress.27 Ang II stimulates
a number of cellular responses via p38, ERK 1/2, and JNK in
several cell types, including vascular smooth muscle cells and
glomerular mesangial cells.22–24,28,29 In proximal tubular cells
derived from Wistar-Kyoto rats, and in porcine proximal
tubular cells stably expressing the rabbit AT1 receptor, Ang II
increases ERK 1/2 and JNK activity.30,31 Similarly, Ang II
activates ERK 1/2 in opossum kidney proximal tubular
cells,32 and induces phosphorylation of p38 MAPK and ERK
1/2 in cultured mouse proximal tubular cells.33
The present studies demonstrate that Ang II rapidly
induces phosphorylation of p38, ERK 1/2, and JNK MAPK
in rat proximal tubular cells. This effect is prevented by
incubation with losartan, suggesting a major role for the AT1
receptor in mediating the response. However, the data also
reveal that preincubation of cells with PD123319 caused a
partial inhibition of the stimulatory effects of Ang II on p38
phosphorylation. This suggests that AT2 receptor activation
may participate in the MAPK response to Ang II, even
though cells were derived from adult rats, where intrarenal
AT2 expression is relatively low. Since losartan completely
blocked the MAPK phosphorylation induced by Ang II, at
micromolar concentration, we cannot rule out the possibility
that some nonspecificity exists, associated with use of these
antagonists. Previous studies have linked AT1 receptor
activation to MAPK stimulation in proximal tubular cells,31
and since Ang II reduces ERK 1/2 phosphorylation in
LLC-PK1 cells expressing the AT2 receptor (and not the AT1
receptor),34 we suggest that the major pathway for MAPK
activation in rat proximal tubular cells is via the AT1 receptor.
The major finding of the present study is that Ang-(1–7)
significantly reduced Ang II-induced phosphorylation of
p38, ERK 1/2, and JNK MAPK in rat proximal tubular cells.
Ang-(1–7) is a heptapeptide component of the renin-angio-
tensin system, and studies indicate that Ang-(1–7) may
inhibit processes that are stimulated by Ang II, such as vaso-
constriction, growth of vascular smooth muscle cells, cell
proliferation, and stimulation of fibrogenic responses.7,8,35
However, the effects of Ang-(1–7) on MAPK signaling in
proximal tubule have not been studied. In this regard, in rat
vascular smooth muscle cells, Ang-(1–7) inhibits Ang II-
stimulated ERK 1/2 phosphorylation,26,36 while having no
effect alone on ERK 1/2, consistent with our results in proxi-
mal tubular cells. Ang-(1–7) has also been shown to inhibit
serum-stimulated cell proliferation in vascular smooth
muscle cells, an effect dependent on release of prostacyclin,
subsequent production of cAMP, and activation of cAMP-
dependent protein kinase A.26 Similarly, in rat inner medul-
lary collecting duct, Ang-(1–7) stimulates cAMP production
and water transport, the latter effect abolished by prosta-
glandin E2 or protein kinase A inhibition.25 In the current
studies in rat proximal tubular cells, in contrast, we observed
no effect of Ang-(1–7) on cAMP production. This suggests
that other signaling pathways mediate the inhibitory effects
of Ang-(1–7) on Ang II responses in the proximal tubule.
Ang-(1–7) has been linked to the production of arachidonic
acid in proximal tubular cells,37 and it is also conceivable that
Ang-(1–7) directly activates cytoplasmic phosphatases, lead-
ing to inhibition of agonist-stimulated MAPK activation.
We have recently demonstrated that the rat proximal
tubule expresses relatively high levels of ACE2,6 an enzyme
that catalyzes the formation of Ang-(1–7), either directly
from Ang II or via conversion of Ang-(1–10) to Ang-(1–9),
followed by ACE-dependent cleavage to Ang-(1–7).2,3 Synth-
esis of Ang-(1–7) via an ACE2-dependent pathway has been
demonstrated in proximal tubule,6 and indeed urinary levels
of Ang-(1–7) are higher than those found in the circulation,
suggesting substantial intrarenal synthesis.38 Furthermore,
Ang-(1–7), ACE2, and mas protein have been immuno-
histochemically localized to mouse proximal tubule, suggest-
ing the existence of a local autocrine/paracrine system for
production and action of this peptide.39 The proximal tubule
also expresses the enzymes necessary for synthesis of Ang II,
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Figure 7 | D-Ala7-Ang-(1–7) reverses the inhibitory effect of Ang-
(1–7) on Ang II-stimulated JNK phosphorylation. Rat proximal
tubular cells were pretreated with D-Ala7-Ang-(1–7) (D-Ala7, 105 M) for
10 min prior to administration of Ang II, with or without Ang-(1–7)
(107 M). Shown is effect on phosphorylation of JNK. *Po0.05 vs
control or vs Ang IIþAng-(1–7), n¼ 5.
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Figure 8 | Effect of Ang-(1–7) on Ang II-stimulated production of
TGF-b1 in rat proximal tubular cells. Cells were treated with Ang II
(107 M) for 48 h, with or without Ang-(1–7) (107 M). Values are
means7s.e.m. *Po0.001 vs control, **Po0.05 vs control (n¼ 7).
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and concentrations of Ang II in the vicinity of this segment
have been reported to be in the nanomolar range, or at least
100-fold higher than those in plasma.40 The current studies
suggest, therefore, that the synthesis of Ang-(1–7) in proximal
tubule could represent an endogenous pathway that limits
the ability of local Ang II to stimulate cell growth responses,
via inhibition of MAPK activation.
Although Ang-(1–7) has limited affinity for Ang II AT1 or
AT2 receptors, its actions in the kidney and other sites appear
to be mediated by distinct cell surface receptors.41 In 2003,
Santos et al.42 identified the G protein-coupled mas protein
as a putative receptor for Ang-(1–7). In the current studies,
we demonstrated the presence of mas mRNA in rat proximal
tubular cells. The existence of a distinct receptor is also
supported by pharmacologic studies. Thus, in water-loaded
rats, the antidiuretic action of Ang-(1–7) is blocked by the
selective Ang-(1–7) receptor antagonist D-Ala7-Ang-(1–7),
which has a very low affinity for classical Ang II receptor
subtypes (AT1 and AT2).
43 Moreover, in bovine aortic endo-
thelial cells, neither AT1- nor AT2-selective receptor antago-
nists significantly competed for 125I-Ang-(1–7) binding.44 In
our studies, we observed a small but nonsignificant stimu-
latory effect of Ang-(1–7) alone on p38 MAPK phosphory-
lation. Studies have reported that the effects of Ang-(1–7)
may be blocked by AT1 receptor antagonists under certain
conditions, suggesting partial agonist activity of Ang-(1–7)
on the AT1 receptor.
45,46 Our data strongly support the exis-
tence of a distinct receptor for Ang-(1–7) in rat proximal
tubular cells, since the inhibitory effect of Ang-(1–7) on
stimulation of all three MAPK by Ang II was completely
reversed by D-Ala7-Ang-(1–7). Moreover, in rat cardiac
myocytes, Ang-(1–7) inhibits phosphorylation of ERK 1/2,
an effect that is completely blocked by transfection of cells
with antisense oligonucleotide to the mas receptor, providing
further support for the role of mas as a distinct binding site
for Ang-(1–7).47
Ang II stimulates the synthesis of TGF-b1 in proximal
tubular cells.20,21 In pathophysiologic states such as diabetic
nephropathy or urinary tract obstruction, Ang II-stimulated
production of TGF-b1 represents a final common pathway
that is thought to accelerate the progression of tubulointer-
stitial fibrosis.48,49 Although the precise mechanisms of
Ang II-induced TGF-b1 expression remain unclear, in mouse
mesangial cells Ang II regulates TGF-b1 production via a
pathway involving MAPK.50 Conversely, TGF-b1 can directly
activate all three MAPK signaling pathways.51 Our data
confirm that Ang II significantly stimulates the secretion of
active TGF-b1 from rat proximal tubular cells. Ang-(1–7)
caused a partial decrease in Ang II-stimulated levels of
TGF-b1, compared to those associated with Ang II alone.
Our results are in agreement with studies by Wolf et al.,21
who showed that transfection of proximal tubular cells with
the c-mas oncogene (encoding the putative receptor for Ang-
(1–7)) caused an inhibition of Ang II-stimulated TGF-b1
production. In the present studies, the stimulation of TGF-b1
secretion remained significantly elevated, compared to
control cells. The data suggest, therefore, that the production
of TGF-b1 mediated by Ang II in rat proximal tubular cells
involves additional pathways besides any of the three MAPKs.
Thus, Ang-(1–7)-mediated production of arachidonic acid,37
or other signals, might be involved in regulating the secretion
of TGF-b1 in proximal tubule.
In summary, our data indicate that in rat proximal tubular
cells, Ang-(1–7) inhibits Ang II-mediated MAPK phosphory-
lation, and partly suppresses Ang II-stimulated increases
in TGF-b1. ACE2-mediated production of Ang-(1–7) may
counteract the effects of locally generated Ang II in the
proximal tubule, thereby protecting against the development
of progressive tubulointerstitial fibrosis, a hallmark of
chronic kidney disease.
MATERIALS AND METHODS
Isolation and culture of rat proximal tubular cells
Suspensions of rat proximal tubules were isolated by collagenase
digestion of renal cortices, followed by Percoll gradient centrifuga-
tion, essentially as described.52 Briefly, kidneys were removed
aseptically from anesthetized 200–250 g male Sprague–Dawley rats,
and renal cortices were dissected, gently minced, and suspended in a
solution consisting of (in mmol/l) 105 NaCl, 24 NaHCO3, 5 KCL,
1.5 CaCL2, 1.0 MgSO4, 2.0 Na2HPO4, 5 D-glucose, 1.0 alanine, 4.0
Na lactate, 10 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
(pH 7.4), 0.2% bovine serum albumin, 0.03% collagenase (type IV;
Sigma, St Louis, MO, USA), and 0.01% soybean trypsin inhibitor
(Sigma) (buffer A). The suspension was gassed with 5% CO2–95%
O2 for 30 min at 371C. After digestion, the cortical suspension was
strained through a 250 mm brass sieve and then centrifuged for 1 min
at 100 g. The pellet was resuspended in buffer A without collagenase
or trypsin inhibitor and recentrifuged three times at 100 g. The pellet
was then applied to a 42% Percoll solution of identical ionic
composition as buffer A, which had been previously chilled to 41C.
The Percoll solution was centrifuged at 26 000 g for 30 min at 41C,
and the digested tissue separated into four distinct bands. The F4
layer, enriched in proximal tubular segments, was removed and
suspended in buffer A without collagenase or trypsin inhibitor and
centrifuged. The final pellet was suspended in culture medium and
tubules were seeded onto culture plates. The procedure yields a
highly purified preparation of proximal tubules (97% by micro-
scopy), and viability of segments was 495%, as determined by
exclusion of trypan blue (10 mg/dl).
Cells plated for culture were initially grown in a defined medium
consisting of Dulbecco’s modified Eagle’s medium-F12, insulin
(5mg/ml), transferrin (5 mg/ml), selenium (5 ng/ml), hydrocortisone
(50 nM), and 3,30,5-triiodo-L-thyronine (2.5 nM), supplemented with
10% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin. At 24 h after plating, cells were switched to defined
medium without serum. The cells were maintained at 371C, in a
humidified environment of 5% CO2 in Dulbecco’s modified Eagle’s
medium/F-12 medium. Experiments were performed on subcon-
fluent cells (B75% confluence) that had been rendered quiescent by
24 h incubation in serum- and hormone-free culture medium.
RT-PCR
RT-PCR was performed to demonstrate the presence of mRNA for
the putative receptor for Ang-(1–7), the mas protein, in rat proximal
tubular cells. Briefly, RNA (1 mg) was isolated from primary cultures
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of rat proximal tubular cells, and rat kidney cortex (RNeasy, Qiagen,
Mississauga, ON, Canada). The RNA was reverse transcribed,
denatured at 941C for 3 min, and then subject to 40 cycles of PCR at
941C for 30 s, 571C for 30 s, and 721C for 45 s, followed by extension
at 721C for 10 min, using a commercial kit (Applied Biosystems,
Foster City, CA, USA). The selected primers were designed to
generate a 313 bp product, corresponding to bp 267–579 of the rat
mas cDNA (GenBank). The upstream primer was 50-ctatgctttagactat
gaactctct-30, and the downstream primer was 50-gaggatggctatgaagat
gatgac-30. PCR products were identified by running samples on
agarose gels stained with ethidium bromide.
Western blotting
After 24 h in hormone- and serum-free medium, subconfluent
proximal tubular cells were incubated for various times (up to
60 min) with Ang II (106–109 M) (Bachem Bioscience Inc., King of
Prussia, PA, USA), followed by immunoblot assays for phosphory-
lated MAPK. In certain experiments, cells were pretreated with
either 107 M Ang-(1–7) (Bachem Bioscience Inc.), 106 M losartan
(Merck Research Laboratories, Rahway, NJ, USA), 106 M PD123319
(Sigma) or 105 M D-Ala7-Ang-(1–7) (Bachem Bioscience Inc.) for
10–20 min prior to application of Ang II. The phosphorylation state
of the MAPK p38, ERK 1/2 and JNK was measured by Western
blotting, as described.34 Briefly, cells were lysed in a buffer consisting
of 62.5 mM Tris-HCl (pH 6.8), 2% w/v sodium dodecyl sulfate, 10%
glycerol, 50 mM DTT, and 0.1% w/v bromophenol blue. The lysate
was then sonicated for 5 s, and boiled for 5 min, followed by
centrifugation at 12 000 g for 5 min to remove insoluble debris. After
quantification of proteins, equal amounts of protein lysates (10 mg)
were run on 10% sodium dodecyl sulfate-polyacrylamide gels and
transferred onto nitrocellulose membranes (Bio-Rad Laboratories,
Ltd, Mississauga, ON, Canada). The membranes were blocked with
5% skim milk in Tris-buffered saline (pH 7.6) containing 0.1%
Tween-20 (TBS-T) for 1 h at room temperature. The membranes
were then incubated for 16 h at 41C with a 1:1000 dilution of
antiphosphospecific antibodies to p38 MAPK (Cell Signaling
Technology, New England Biolabs Ltd, Pickering, ON, Canada),
ERK 1/2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
and JNK (Santa Cruz Biotechnology, Inc.). Membranes were then
incubated with 1:2000 dilution of horseradish peroxidase-conju-
gated secondary antibody (Amersham, Piscataway, NJ, USA), and
then washed. Phosphorylated proteins were detected by enhanced
chemiluminescence (Amersham) on Hyperfilm (Amersham). Pre-
stained standards were used as molecular weight markers (Bio-Rad).
To control for protein loading, all membranes were stripped and
re-probed with antibodies to unphosphorylated p38 MAPK (Cell
Signaling Technology), ERK 1/2 (Santa Cruz Biotechnology, Inc.),
and JNK (Santa Cruz Biotechnology, Inc.). Signals for phosphory-
lated MAPK proteins on Western blots were quantified by
densitometry and corrected for unphosphorylated protein levels,
using an image-analysis software program (Kodak Densitometer
1S440CF). For ERK, graphic data show the p42 signal, while for
JNK, graphic data indicate the p54 signal. Similar effects were
observed on p44 ERK and p46 JNK.
Enzyme-linked immunosorbent assay assay for TGF-b1
The secretion of active TGF-b1 from cultured rat proximal tubular
cells was quantified using a commercially available enzyme-linked
immunosorbent assay (R&D Systems, Minneapolis, MN, USA),
following the manufacturer’s instructions. For each experiment, a
TGF-b1 standard curve was constructed using varying concentra-
tions of recombinant human TGF-b1 protein, and a curve-fitting
software program was used to quantify TGF-b1 protein concentra-
tion in the culture media. All data were corrected for cell protein
content, measured by Bradford assay.
cAMP assay
Quiescent primary cultures of rat proximal tubular cells on plastic
dishes were incubated in Dulbecco’s modified Eagle’s medium/F12
medium supplemented with isobutyl-methylxanthine (104 M) and
0.5% bovine serum albumin, along with either Ang-(1–7) (107 M),
Ang II (107 M), PTH (107 M), or forskolin (104 M), for 10 or
30 min. The culture medium was then aspirated and replaced with
ice-cold 10% trichloroacetic acid (vol/vol). After 30 min, the
samples were extracted four times with four volumes of water-
saturated ether. The pH of the samples was adjusted to 7.0 with
Tris-HCl. Sample aliquots were assayed for cAMP, using a
radioligand competitive binding assay kit (Intermedico, Markham,
ON, Canada). Experiments were performed in duplicate, and results
are expressed as pmoles cAMP/mg protein.
Statistical analysis
Results are presented as means7s.e. Significance, considered as
Po0.05, was determined by analysis of variance, with Bonferroni
correction, in all cases involving multiple comparisons.
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